Legacy Capital Wealth Partners LLC Has $310,000 Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Legacy Capital Wealth Partners LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 10.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 531 shares of the company’s stock after selling 64 shares during the period. Legacy Capital Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $310,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the business. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $26,000. Thompson Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company during the third quarter worth $27,000. Legacy Financial Group LLC acquired a new stake in Eli Lilly and Company during the third quarter valued at $35,000. Optiver Holding B.V. purchased a new position in Eli Lilly and Company in the third quarter valued at about $36,000. Finally, Family CFO Inc acquired a new position in Eli Lilly and Company in the 3rd quarter worth about $40,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $737.33 on Tuesday. The firm has a market capitalization of $700.58 billion, a PE ratio of 127.13, a PEG ratio of 1.60 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 1-year low of $392.26 and a 1-year high of $800.78. The business’s 50 day moving average is $760.89 and its 200-day moving average is $668.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business’s revenue was up 28.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.09 earnings per share. Sell-side analysts predict that Eli Lilly and Company will post 12.51 earnings per share for the current year.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on LLY. Morgan Stanley boosted their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Truist Financial reissued a “buy” rating and issued a $850.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 22nd. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Finally, Barclays increased their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.